| Stage | CRUS | % of rev | EXPE | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $460M | 100.00% | $4.3B | 100.00% | EXPE ×9.39 |
| Gross profit | $242M | 52.61% | $4.3B | 100.00% | EXPE +47.4pp |
| Operating income | $84M | 18.37% | $800M | 18.54% | EXPE +0.2pp |
| Pre-tax income | $94M | 20.48% | $1.0B | 23.80% | EXPE +3.3pp |
| Net income | $77M | 16.72% | $875M | 20.28% | EXPE +3.6pp |
| Stage | CRUS | EXPE | Gap · A − B |
|---|---|---|---|
| Revenue | $460M100.00% | $4.3B100.00% | EXPE ×9.39 |
| Gross profit | 52.61%$242M | 100.00%$4.3B | EXPE +47.4pp |
| Operating income | 18.37%$84M | 18.54%$800M | EXPE +0.2pp |
| Pre-tax income | 20.48%$94M | 23.80%$1.0B | EXPE +3.3pp |
| Net income |
| 16.72%$77M |
| 20.28%$875M |
| EXPE +3.6pp |
No shared counterparties.